SM
SAGE

Sabby Management’s Sage Therapeutics SAGE Stock Holding History

Sabby Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,379
Closed -$244K – 254
2017
Q1 		$240K Buy
+3,379
New +$198K 0.01% 212
2016
Q3 		– Sell
-68,950
Closed -$2.81M – 334
2016
Q2 		$2.08M Sell
68,950
-31,050
-31% -$1.04M 0.11% 107
2016
Q1 		$3.21M Buy
100,000
+91,877
+1,131% +$3.23M 0.16% 66
2015
Q4 		$474K Sell
8,123
-31,896
-80% -$1.58M 0.03% 240
2015
Q3 		$1.69M Buy
40,019
+14,939
+60% +$921K 0.07% 178
2015
Q2 		$1.83M Buy
+25,080
New +$1.61M 0.07% 172

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sabby Management's SAGE Position: Q2 2017 in Review

Sabby Management sold out of Sage Therapeutics (SAGE) in Q2 2017, closing a stake of 3,379 shares — an estimated $244K sold.

Sabby Management first reported a position in SAGE in Q2 2015 and held it in 6 quarters. The position peaked at $3.21M in Q1 2016. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2017.

  • Sabby Management reported no remaining Sage Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Sabby Management sold 3,379 Sage Therapeutics shares in Q2 2017, an estimated $244K.
  • Sabby Management first reported a position in Sage Therapeutics in Q2 2015 and held it in 6 quarters.
  • Sabby Management's Sage Therapeutics position peaked at $3.21M in Q1 2016.
  • 191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.